Merck KGaA pushes for MDxHealth's diagnostic to become full companion to brain cancer drug
This article was originally published in Scrip
Executive Summary
Merck KGaA is extending its agreement with diagnostics company MDxHealth for the use of the MGMT assay in Merck KGaA's brain cancer clinical trials.